Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability - Test2 - elhamkhani - TriplyDB

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

http://www.wikidata.org/entity/Q24610709

about

Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation Eribulin in Cancer Treatment Simulated cytoskeletal collapse via tau degradation Advances in sarcoma diagnostics and treatment Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival Marine-Derived Pharmaceuticals - Challenges and Opportunities Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells Natural products as sources of new drugs over the 30 years from 1981 to 2010 Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules Efficacy of eribulin in breast cancer: a short report on the emerging new data.Oncology nursing support for safe and effective use of eribulin in metastatic breast cancer Integrated systems pharmacology analysis of clinical drug-induced peripheral neuropathy.Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.Marine natural products: a new wave of drugs?Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states Eribulin mesylate targets human telomerase reverse transcriptase in ovarian cancer cells.Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program Interactions of halichondrin B and eribulin with tubulin.Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer.Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case Series Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies Eribulin disrupts EB1-microtubule plus-tip complex formation Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer.Eribulin targets a ch-TOG-dependent directed migration of cancer cells A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer.Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance Centriolar CPAP/SAS-4 Imparts Slow Processive Microtubule Growth.Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity.In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy.Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer.Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition.

P2860

Q26784048-0CBC7833-0D52-4649-A10A-65AD7AE75181 Q26799328-68D4835D-C511-4BB2-AF62-136532A94B4D Q27315041-C6AE8DCD-7E7D-4187-80E8-2933ED5F748F Q28069695-DC95DC87-93BC-484C-BB69-AD2CE53C9B86 Q28074125-F07769D0-8CBE-47CC-86B4-624EF885EFAA Q28075572-697ED7A5-88DC-4CEE-9ED9-FB5768CA74E6 Q28542669-463E925C-78EC-40B7-AF52-5968A6E6F5F9 Q29616640-B45A8EA8-4D60-4CCA-9C4B-9E81F0198DA4 Q30496972-26854EB6-CAD8-424F-B7E0-809E619F8031 Q31167441-F8388DB0-EAA4-48AB-A36F-EF1821768BA3 Q33618680-FBDD8182-048E-4ADD-9E15-FC0B92FF134E Q33733061-8D63CC7E-D71E-4C98-B219-C880B5768795 Q33858197-324D1655-38C4-49A1-96A3-F6DDE7DAAF19 Q34007283-76074A2B-25F3-497E-A066-18F6A7A1A876 Q34062522-B9578997-DBC4-4764-B250-899C7FCCE10B Q34406761-A173B415-6ED4-40AE-8847-B36B16A2F7C7 Q34466428-57BFBF0C-5E42-4D83-9082-FBD9A6A15DC5 Q34683835-0AC0AA3E-9616-4064-B29F-CECD6B2CE210 Q35088820-FCF9EE65-0D41-4B7B-A155-44E2D0ADECFD Q35599745-6B8A471D-02E5-4562-AED7-0D63E9024380 Q35647947-1A67FB3C-C4C0-4AA8-AC1E-D37C86374EF1 Q35721526-72CED07C-30EB-4BAB-98DA-E458743B1295 Q36020972-AF0B05B4-A7CA-4D38-9951-82664015E538 Q36079935-A590437A-D084-4C3A-8FF9-8BD179E1C983 Q36187429-A86BAA1B-1CE4-45A2-82D7-36FA13C093F5 Q36273796-B9D2BA17-D1BC-4FAC-ADB8-F8D3F5540694 Q36411072-A30D721B-A680-4FE8-A304-766D56D1AC4C Q36502730-1EA3D1CE-2788-40BD-854B-46A2F22FF930 Q36561555-8C098E55-64A9-4443-8D2D-2E771A449F3D Q36614786-1E42C538-0B34-4205-BD7C-4037907FA885 Q36629243-404A8F4F-3AE3-45E1-8E36-0C79749F56C4 Q36742259-A7C05485-F357-444F-8FB3-733519DCCDA8 Q36922483-865919D0-C9A3-4BCD-8324-7129DEBC4CDB Q36945922-308F260C-AE6A-40C7-AFFE-75320D9EA5CF Q36963585-7E9DAEBB-C8CA-4D03-9ABC-BCF650171C64 Q36964337-C1647C5E-177C-483E-B446-7947651A09C2 Q37067999-A02999CF-1E53-484C-AD36-4208831689EB Q37177111-602045E4-DAE8-4D68-A423-B41730BF0BB5 Q37356090-13643468-CDED-4C11-B55B-A639D5ECE110 Q37419295-0DAC7877-D87E-4BEA-9D7D-6007EAE80044

P2860

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

http://www.wikidata.org/entity/Q24610709

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Eribulin binds at microtubule ...... o suppress dynamic instability

@ast

Eribulin binds at microtubule ...... o suppress dynamic instability

@en

Eribulin binds at microtubule ...... o suppress dynamic instability

@nl

type

label

Eribulin binds at microtubule ...... o suppress dynamic instability

@ast

Eribulin binds at microtubule ...... o suppress dynamic instability

@en

Eribulin binds at microtubule ...... o suppress dynamic instability

@nl

prefLabel

Eribulin binds at microtubule ...... o suppress dynamic instability

@ast

Eribulin binds at microtubule ...... o suppress dynamic instability

@en

Eribulin binds at microtubule ...... o suppress dynamic instability

@nl

P1433

Q24610709-A2A6DFC2-1D80-4B5D-ABD3-CFE36C83DCC4

P1476

Q24610709-C326992A-98FF-4C9D-9510-7B2D1B5D15A5

P2093

Q24610709-0990F6D6-C205-479D-8A45-F23FBAE3FF69

Q24610709-5105E64C-A140-4354-96D6-978ECF257B9C

Q24610709-6FBF88F5-4D40-4139-987D-9D50FB32AAFF

Q24610709-89FA882A-39DE-4660-89D2-1FC51AC61D6D

Q24610709-8F153F7A-E4F7-4E80-9812-94B75F031883

Q24610709-BB9D3D12-843F-45F1-9A4F-4F52A7B0C064

Q24610709-C9695688-8063-45C2-92DD-52E722731A3E

P2860

Q24610709-01F39E4F-15C1-44DA-B5F2-C0AFD6E8D7D3

Q24610709-0D8FC4DF-5100-4BA8-9CC9-914140821B75

Q24610709-0E68FBE7-8171-4AD4-85D6-00C2236AC0D0

Q24610709-1CC9920D-E17D-41CD-BD19-12033E3A1151

Q24610709-281A6242-3566-4D19-A078-18C784212B8A

Q24610709-2E4F365E-595F-46DB-86EE-A01CECCACAB3

Q24610709-3A99618F-92BB-4182-9459-C845976C0517

Q24610709-3CDE196B-C021-4EF2-A51E-AAA8989993C4

Q24610709-3EF055EF-708C-4A5A-B48E-2CA2CF11F548

Q24610709-46D152D5-F850-441B-93C6-24F5447B8897

P304

Q24610709-E17183F6-4217-4777-8CB8-436795C98758

P31

Q24610709-94755EF8-4AF7-44E2-A26B-122D2B62BE4F

P3181

Q24610709-0EBE8A42-82A4-4E6F-9779-09E92B507D01

P356

Q24610709-370DB1FF-9B7B-4F4B-B0F2-92AFCA4D4E05

P407

Q24610709-7961782B-7738-46C6-B000-1AAF30CDAC09

P433

Q24610709-B2EB7F62-DFE6-4184-BC54-DDFADE269B84

P478

Q24610709-D5E98544-3069-428D-9367-AF35DE16C637

P577

Q24610709-2647F957-6376-42CF-AD38-4FFCB79FE8FF

P5875

Q24610709-0AA2A7EE-58E8-43D6-90AB-236FFA88C089

P698

Q24610709-AC51D6DC-36B2-4589-8E51-B01A560A3E93

P921

Q24610709-F1699FE6-A582-4F8B-91AF-4508708A4447

P932

Q24610709-B61AC441-72D1-4861-8CEB-2748C0DD13DA

P3181

P356

P1433

P1476

Eribulin binds at microtubule ...... o suppress dynamic instability

@en

P2093

Bruce A Littlefield

http://www.w3.org/2001/XMLSchema#string

Bryan M Lewis

http://www.w3.org/2001/XMLSchema#string

Jennifer A Smith

http://www.w3.org/2001/XMLSchema#string

Leslie Wilson

http://www.w3.org/2001/XMLSchema#string

Mary Ann Jordan

http://www.w3.org/2001/XMLSchema#string

Olga Azarenko

http://www.w3.org/2001/XMLSchema#string

Xiaojie Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Structural insight into the inhibition of tubulin by vinca domain peptide ligands

In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B

Microtubules as a target for anticancer drugs

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data

Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B.

Dynamic instability of individual microtubules analyzed by video light microscopy: rate constants and transition frequencies.

Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients

P304

1331-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1937265

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/BI901810U

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40765890

http://www.w3.org/2001/XMLSchema#string

P698

20030375

http://www.w3.org/2001/XMLSchema#string

P921

P932

2846717

http://www.w3.org/2001/XMLSchema#string